Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- NKF 2025 Survey: Patients Want More Home Dialysis Options Posted 01-13-2025
- Annual PD Machine Operating Cost is $24/mo or Less Posted 01-13-2025
- Premier Dialysis Videos: How to Read and Use PD Bags From Other Countries Posted 01-13-2025
- Medicare’s 2025 Physician Fee Schedule Posted 01-13-2025